SCHEMBL13628299

SCHEMBL13628299

CCCCc1cccc2c1/C(=N/O)C(=O)N2Cc1cc(F)cc2c1OCOC2

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCRTR1 O43613 1/20 0.36
HCRTR2 O43614 1/20 0.36
NPC1 O15118 3/20 0.36
RAB9A P51151 3/20 0.36
POLB P06746 2/20 0.36
NPSR1 Q6W5P4 1/20 0.36
TSHR P16473 6/20 0.35
GALR3 O60755 1/20 0.34
NR2F2 P24468 1/20 0.34
MAPK8 P45983 1/20 0.33
ALDH1A1 P00352 3/20 0.32
TDP1 Q9NUW8 1/20 0.32
CXCR5 P32302 1/20 0.32
CYP3A4 P08684 2/20 0.31
CYP2C9 P11712 2/20 0.31
CYP2C19 P33261 2/20 0.31
CYP2D6 P10635 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
USP2 O75604 1/20 0.31
GAA P10253 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13628280 0.92 HCRTR1 (0.38) HCRTR1HCRTR2NPC1RAB9APOLB
SCHEMBL13628244 0.87 NPC1 (0.38) HCRTR1HCRTR2NPC1RAB9APOLB
SCHEMBL13628282 0.84 NPC1 (0.36) HCRTR1HCRTR2NPC1RAB9APOLB
SCHEMBL13628153 0.83 HCRTR1 (0.37) HCRTR1HCRTR2NPC1RAB9APOLB
SCHEMBL13628139 0.83 NPC1 (0.37) HCRTR1HCRTR2NPC1RAB9APOLB
SCHEMBL13628142 0.83 HCRTR1 (0.35) HCRTR1HCRTR2NPC1RAB9APOLB
SCHEMBL13628245 0.82 NPC1 (0.37) HCRTR1HCRTR2NPC1RAB9APOLB
SCHEMBL13628194 0.82 TSHR (0.39) HCRTR1HCRTR2NPC1RAB9APOLB
SCHEMBL13628140 0.82 HCRTR1 (0.35) HCRTR1HCRTR2NPC1RAB9APOLB
SCHEMBL21067775 0.81 POLB (0.36) HCRTR1HCRTR2NPC1RAB9APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7612065-B2 Inhibitors of c-JUN N-terminal kinases (JNK) VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-11-03 US disclosed
US-7612065-B2 Inhibitors of c-JUN N-terminal kinases (JNK) VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-11-03 US disclosed
US-20080033022-A1 Inhibitors of c-Jun N-terminal kinases (JNK) SALITURO FRANCESCO G 2008-02-07 US disclosed
US-20080033022-A1 Inhibitors of c-Jun N-terminal kinases (JNK) SALITURO FRANCESCO G 2008-02-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080033022-A1 Inhibitors of c-Jun N-terminal kinases (JNK) MAP3K1, JUN, MAP3K7 HCRTR1 4016/4885HCRTR2 4025/4885NPC1 1715/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.